These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 11398170

  • 1. Comparison of prazosin, terazosin and tamsulosin: functional and binding studies in isolated prostatic and vascular human tissues.
    Amadesi S, Varani K, Spisani L, Daniele C, Turini A, Agnello G, Zamboni P, Borea PA, Geppetti P.
    Prostate; 2001 Jun 01; 47(4):231-8. PubMed ID: 11398170
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies.
    Kenny BA, Miller AM, Williamson IJ, O'Connell J, Chalmers DH, Naylor AM.
    Br J Pharmacol; 1996 Jun 01; 118(4):871-8. PubMed ID: 8799556
    [Abstract] [Full Text] [Related]

  • 3. Functional antagonistic activity of Rec 15/2739, a novel alpha-1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery.
    Testa R, Guarneri L, Taddei C, Poggesi E, Angelico P, Sartani A, Leonardi A, Gofrit ON, Meretyk S, Caine M.
    J Pharmacol Exp Ther; 1996 Jun 01; 277(3):1237-46. PubMed ID: 8667184
    [Abstract] [Full Text] [Related]

  • 4. Tamsulosin: alpha1-adrenoceptor subtype-selectivity and comparison with terazosin.
    Muramatsu I, Taniguchi T, Okada K.
    Jpn J Pharmacol; 1998 Nov 01; 78(3):331-5. PubMed ID: 9869267
    [Abstract] [Full Text] [Related]

  • 5. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
    Kyprianou N, Benning CM.
    Cancer Res; 2000 Aug 15; 60(16):4550-5. PubMed ID: 10969806
    [Abstract] [Full Text] [Related]

  • 6. Alpha1L-adrenoceptors mediate contractions of the isolated mouse prostate.
    Gray KT, Ventura S.
    Eur J Pharmacol; 2006 Jul 01; 540(1-3):155-61. PubMed ID: 16716294
    [Abstract] [Full Text] [Related]

  • 7. Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia.
    Lepor H, Gup DI, Baumann M, Shapiro E.
    Urology; 1988 Dec 01; 32(6 Suppl):21-6. PubMed ID: 2462301
    [Abstract] [Full Text] [Related]

  • 8. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
    Keledjian K, Kyprianou N.
    J Urol; 2003 Mar 01; 169(3):1150-6. PubMed ID: 12576871
    [Abstract] [Full Text] [Related]

  • 9. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
    Tahmatzopoulos A, Kyprianou N.
    Prostate; 2004 Apr 01; 59(1):91-100. PubMed ID: 14991869
    [Abstract] [Full Text] [Related]

  • 10. New alpha1-adrenoceptor antagonist, JTH-601, shows more than 10 times higher affinity for human prostates than arteries.
    Takahashi M, Taniguchi T, Murata S, Okada K, Moriyama N, Yamazaki S, Muramatsu I.
    J Urol; 1999 Apr 01; 161(4):1350-4. PubMed ID: 10081906
    [Abstract] [Full Text] [Related]

  • 11. An investigation of the uroselective properties of four novel alpha(1a)-adrenergic receptor subtype-selective antagonists.
    Pulito VL, Li X, Varga SS, Mulcahy LS, Clark KS, Halbert SA, Reitz AB, Murray WV, Jolliffe LK.
    J Pharmacol Exp Ther; 2000 Jul 01; 294(1):224-9. PubMed ID: 10871316
    [Abstract] [Full Text] [Related]

  • 12. In vivo measurement by [3H]Tamsulosin of alpha1 adrenoceptors in rat tissues in relation to the pharmacokinetics.
    Yamada S, Ohkura T, Deguchi Y, Kimura R.
    J Pharmacol Exp Ther; 1999 Jun 01; 289(3):1575-83. PubMed ID: 10336555
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part I.
    Leonardi A, Hieble JP, Guarneri L, Naselsky DP, Poggesi E, Sironi G, Sulpizio AC, Testa R.
    J Pharmacol Exp Ther; 1997 Jun 01; 281(3):1272-83. PubMed ID: 9190863
    [Abstract] [Full Text] [Related]

  • 14. Pharmacological characterization of isolated human prostate.
    Kester RR, Mooppan UM, Gousse AE, Alver JE, Gintautas J, Gulmi FA, Abadir AR, Kim H.
    J Urol; 2003 Sep 01; 170(3):1032-8. PubMed ID: 12913765
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Characterization of alpha 2-adrenoceptors mediating contraction of dog saphenous vein: identity with the human alpha 2A subtype.
    MacLennan SJ, Luong LA, Jasper JR, To ZP, Eglen RM.
    Br J Pharmacol; 1997 Aug 01; 121(8):1721-9. PubMed ID: 9283709
    [Abstract] [Full Text] [Related]

  • 17. Design and synthesis of novel alpha1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia.
    Nagarathnam D, Wetzel JM, Miao SW, Marzabadi MR, Chiu G, Wong WC, Hong X, Fang J, Forray C, Branchek TA, Heydorn WE, Chang RS, Broten T, Schorn TW, Gluchowski C.
    J Med Chem; 1998 Dec 17; 41(26):5320-33. PubMed ID: 9857099
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the alpha-adrenoceptor characteristics in human and canine prostate.
    Hieble JP, Boyce AJ, Caine M.
    Fed Proc; 1986 Oct 17; 45(11):2609-14. PubMed ID: 2428671
    [Abstract] [Full Text] [Related]

  • 19. Quantitative imaging in live human cells reveals intracellular alpha(1)-adrenoceptor ligand-binding sites.
    Mackenzie JF, Daly CJ, Pediani JD, McGrath JC.
    J Pharmacol Exp Ther; 2000 Aug 17; 294(2):434-43. PubMed ID: 10900216
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.